Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
about
Structural and functional alterations of FLT3 in acute myeloid leukemiaCombinatorial biosynthesis of antitumor indolocarbazole compoundsLestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disordersMolecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyAcute Myeloid Leukemia: A Concise ReviewCIViC databaseMutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic LeNovel therapeutic options in Acute Myeloid LeukemiaNovel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaFLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewGenetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibSelective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia PatientsFLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDToxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.Taking a Bad Turn: Compromised DNA Damage Response in LeukemiaPatterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaPhase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaPreclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.The Biology and Targeting of FLT3 in Pediatric Leukemia.FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1.Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy.Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasPrognostically important molecular markers in cytogenetically normal acute myeloid leukemia.Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.The Future of Targeting FLT3 Activation in AML.
P2860
Q24338964-ECCC7747-89E1-45CC-ACCA-72A1BF887676Q24557524-29895AAF-EAAD-4163-9AF5-DFA37F07A3C5Q24657681-EEA802C7-2310-420E-BB9C-3B29430F6045Q26749870-38288CAC-32C4-4E32-A7E7-BE3A80F8EE41Q26766719-ED7F30AA-2053-4A6C-8139-DB0D2648BBD9Q27612411-8DFE0B84-D581-4510-BC6D-E4B304EDB514Q27851423-ABE2C702-8B12-4259-B5BE-0F8C09B851F5Q27853031-E5B2D098-EA80-4DF5-8062-8389FCE5B5B9Q28069889-6DE68761-38FD-4D10-91E0-808BE8154503Q28075654-02088282-1698-4876-94A9-E221F17B8DEFQ28289859-A98A8340-B116-4C17-9F77-82C0FAF3ACC2Q28301344-D0F91222-6C35-4B4C-8A03-667B73D62CACQ33270804-D4CE8CFF-C984-42A5-B896-1615268B6D2FQ33387514-608DFA59-74B2-44C5-A03C-4E96E4280EBAQ33402522-9E7068CB-64E4-46F0-BE88-39FF0B6DFD73Q33442949-3E66E2D9-FA19-44A1-97C8-82FD07862551Q33555287-29AD44FD-3F3F-49A4-865E-A19D6E3FC6D3Q33680292-91775E95-5581-4A27-B402-54FEFC1801E1Q33710062-8991A1E5-F313-4E12-9E10-CD8748ED8732Q33749036-EB4C4297-512E-41C2-9D12-8450C56D7BEAQ33767026-0DFC8EBA-995B-47BA-89BE-9E7410CB1196Q33798909-0A91BF57-72B2-41B7-9E5E-DF29E3DCF522Q33801811-10B04E42-A196-4C4E-ABE1-235991C47125Q33855938-B2D11543-0E07-4AF9-89B2-5AFF66C30607Q33913329-9805C849-F00A-4029-BB25-26477DF6EBAEQ33986236-8061D5E4-0BDD-47DF-BB48-338D8E3F9F73Q34004131-26D6E962-7754-49B7-B4D1-DAD20F14F444Q34013882-C964BEF4-9775-4A50-8DFD-CB2D2DC1B674Q34055511-C112FCFC-A036-414F-A573-9B9D6E899F41Q34063343-8E009D0A-E87A-407C-993E-1F447014BF38Q34095013-54C2DCC3-0754-434B-8025-999FA99BAAA3Q34097586-AC8D48E3-8903-40C2-8A6B-3F67233DFAA5Q34229555-68B5BBFF-22A7-4E99-A1BD-31F7A5CA48C6Q34350591-2B9E03F8-4E82-4283-93AF-6056F95A2590Q34412520-D612DDF0-7537-464C-929D-FDC918F26914Q34450478-D4B067E8-4C40-472C-BDD0-C9E1C74C703DQ34451540-11809F69-06EC-4236-AB02-157C663768F2Q34522735-AEB824D1-FECB-4A0A-BCD4-D44B6EC34F91Q34549193-019656B9-F15D-4A49-8D7F-1CDAC9C2966EQ34555386-74AD10B6-44C5-44F4-9B14-8FEE2C0B1E6A
P2860
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Single-agent CEP-701, a novel ...... actory acute myeloid leukemia.
@ast
Single-agent CEP-701, a novel ...... actory acute myeloid leukemia.
@en
Single-agent CEP-701, a novel ...... actory acute myeloid leukemia.
@nl
type
label
Single-agent CEP-701, a novel ...... actory acute myeloid leukemia.
@ast
Single-agent CEP-701, a novel ...... actory acute myeloid leukemia.
@en
Single-agent CEP-701, a novel ...... actory acute myeloid leukemia.
@nl
prefLabel
Single-agent CEP-701, a novel ...... actory acute myeloid leukemia.
@ast
Single-agent CEP-701, a novel ...... actory acute myeloid leukemia.
@en
Single-agent CEP-701, a novel ...... actory acute myeloid leukemia.
@nl
P2093
P3181
P1433
P1476
Single-agent CEP-701, a novel ...... actory acute myeloid leukemia.
@en
P2093
B Douglas Smith
Donald Small
Jeffrey Allebach
Karin Berg
Kathleen M Murphy
Mark Levis
Miloslav Beran
Tianna Dauses
P304
P3181
P356
10.1182/BLOOD-2003-11-3775
P407
P577
2004-05-15T00:00:00Z